Press Releases

NEW YORK, June 3, 2024 /PRNewswire/ -- Hach Rose Schirripa & Cheverie, LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of law by certain officers and directors at Global Cord Blood Corporation (OTCPK: CORBF) ("Global Cord" or the "Company").  Global Cord is a life sciences enterprise dedicated to the storage of umbilical cord blood stem cells.  The Company offers cord blood testing, processing, and storage services... (continue reading...)

NEW YORK, NY / ACCESSWIRE / June 3, 2024 / Recruiter.com Group, Inc. (NASDAQ: RCRT)(NASDAQ: RCRTW) (the "Company") today announced the pricing of a registered direct offering for the sale and issuance of up to 400,000 shares of the Company's common stock to a small group of accredited investors at a price per share of $1.00.

The transactions are expected to close on or about June 5, 2024, subject to the satisfaction of customary closing conditions.

The shares of common... (continue reading...)

TCX-101 Clinical Program: TCR T-Cell therapy product candidate (BSB-1001) to be delivered simultaneously with allogeneic stem cell transplant in patients with active disease or high risk of relapse 

First patient to be enrolled in 4Q2024

Nomination of Three additional novel TCR candidates expand HLA population coverage and addressable market size

TCX 102 Development Program: Autologous TCR-based cell therapy program will target AML patients with mutated NPM-1

IND... (continue reading...)

73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy1

CHICAGO, June 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. The data show CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) significantly improved progression-free survival (PFS) compared to standard... (continue reading...)

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, is reporting its first-quarter 2024 revenues. According to the report, the company saw revenues of $408,532 while also strengthening its balance sheet with the completion of an $8.4 million private placement involving existing and new shareholders; shares for the placement were offered at $4 per share. Nutriband also reported a cash position of $8,347,739. In the report, the company... (continue reading...)